Co-pay programs spur new offering

Pharma's increased investment in co-pay card programs has led research firm TargetRx to launch a product offering more insight into their adoption and use.

The new product couples the firm's attitudinal and prescribing databases with a physician-segmentation tool to “hone in on and predict which types of physicians marketers should focus on and which messages should be emphasized,” as well as enable marketers to adjust their programs during implementation, according to a statement.

As an adherence tool, co-pay card programs are becoming more common amid the rise of competition among branded drugs and pharma's decreased DTC spending.

“By understanding which physicians are most motivated to recommend co-pay cards to patients, we can help make sure these programs are successful, and even more importantly, ensure that these incentives are making it into the hands of the patients who need it most,” said Craig Scott, TargetRx CEO.

You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.